IYH - iShares U.S. Healthcare ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
187.30
-0.13 (-0.07%)
As of 11:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close187.43
Open187.00
Bid187.23 x 800
Ask187.31 x 800
Day's Range187.25 - 187.82
52 Week Range169.96 - 204.83
Volume17,053
Avg. Volume107,324
Net Assets2.1B
NAV185.80
PE Ratio (TTM)N/A
Yield1.89%
YTD Return2.60%
Beta (3Y Monthly)0.98
Expense Ratio (net)0.43%
Inception Date2000-06-12
Trade prices are not sourced from all markets
  • Forget Trade Fears, Invest in Defensive Sector ETFs
    Zacks13 days ago

    Forget Trade Fears, Invest in Defensive Sector ETFs

    Investors are seeking to beat the fresh tariff woes by betting on defensive sectors like utilities, real estate, healthcare and consumer staples. We have highlighted one ETF each from these four zones.

  • Two Healthcare Stocks in the XLV Fund Stand Out
    InvestorPlace16 days ago

    Two Healthcare Stocks in the XLV Fund Stand Out

    Healthcare stocks have fallen somewhat out of favor, as tech and faster growing industries have lead the rally in equities this year. There is a prevailing notion that healthcare stocks are defensive, given their business models and the dividends they pay to their shareholders. However, there are standouts in the sector that are poised to deliver growth, spurred by new approvals and new markets.Source: Shutterstock For those looking for a diversified approach to investing in healthcare stocks, Health Care SPDR (NYSEARCA:XLV) and iShares Dow Jones US Healthcare (NYSEARCA:IYH) are good options that are relatively liquid. The two funds track each other very closely, though there is a slight difference between their yields. XLV yields 1.6%, while IYH has a slightly higher yield of 1.9%. * 7 Energy Stocks to Buy to Light Up Your Portfolio For investors looking to bet on individual stocks, Merck & Co (NYSE:MRK) and AbbVie I(NYSE:ABBV) look like particularly good options. Within the XLV fund, MRK stock makes up 6% of overall holdings and ABBV stock accounts for 3.5% of its assets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMRK stock and ABBV stock are primed to bounce back after both dropped slightly recently. Their performance should help offset any potential weakness of the fund's other holdings, including Johnson & Johnson (NYSE:JNJ).JNJ stock is by far XLV's largest holding, comprising over 11% of its total assets. Though I have concerns about the legal risks facing JNJ stock, the benefit of owning the index is that its diversification reduces the risk posed by each stock. Healthcare Stocks to Buy: MRKMerck demonstrated its ability to execute on its global strategy in the first quarter, generating double-digit percentage sales and earnings per share growth, no small feat, considering that the market cap of MRK stock is over $200 billion. MRK's investments in research and development are clearly paying off, and the owners of MRK stock should be very positive about the company's 2019 outlook.The company's China business generated a large part of its growth, driven by high sales of its oncology drugs and vaccines there. Excluding the negative impact of currency fluctuations, its China sales soared 67% year-over-year. China is a huge market with significant demand, but it's not an easy nut to crack. Many multinational corporations spanning various industries have struggled to generate profits there. Merck's ability to drive sales in China bodes well for its future growth and for MRK stock.On the oncology front, the FDA's approval of MRK's Keytruda for a number of indications, including advanced renal cell carcinoma and melanoma with lymph nodes, was a big win for MRK stock. The EU also approved Keytruda in combination with chemotherapy. Sales of Keytruda were up 55% year-over-year in Q1.Expect further approvals of MRK's oncology drugs throughout the year to provide a boost to MRK stock. A number of the company's animal-health treatments could also be approved. Healthcare Stocks to Buy: ABBVABBV stock hasn't maintained as much upward momentum as I would have expected after it reported very solid Q1 results. This global pharmaceutical company focuses on four therapeutic areas: immunology, oncology, virology and neuroscience. ABBV is a healthcare stock that has a lot of potential, given the strength of the company's pipeline.ABBV's quarterly sales and earnings both beat expectations, leading ABBV to increase its full-year EPS guidance from $7.26 to $7.36. Most importantly, the company's pipeline advanced meaningfully. Notably, the FDAand the Japanese Ministry of Health, Labour and Welfare both approved the company's SKYRIZI treatment, which could improve the standard of care of psoriasis.Those were big wins in a therapeutic area with a great deal of long-term potential. ABBV has multiple other products making their way through the approval process, setting the stage for ABBV stock to benefit from multiple positive catalysts in the near future.In oncology, AbbVie announced a strategic partnership with Teneobio, a biotechnology company that's developing a new class of biologics for the treatment of cancer, autoimmunity and infectious diseases. The two companies have agreed to develop and commercialize a biologic calledTNB-383B for the potential treatment of multiple myeloma.ABBV' has several other ongoing collaborations that will expand its oncology research platform, enabling it to develop life-changing treatments andmeaningfully boost ABBV stock.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best Stocks to Buy for May * 7 Stocks Worth Buying When They're Down * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post Two Healthcare Stocks in the XLV Fund Stand Out appeared first on InvestorPlace.

  • Can Q1 Earnings Lift Healthcare ETFs Higher?
    Zackslast month

    Can Q1 Earnings Lift Healthcare ETFs Higher?

    With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

  • UnitedHealth Falls Despite Q1 Beat, Healthcare ETFs in Focus
    Zackslast month

    UnitedHealth Falls Despite Q1 Beat, Healthcare ETFs in Focus

    UnitedHealth Group reported robust first-quarter 2019 results. The company breezed past the Zacks Consensus Estimate on both earnings and revenues and raised its full-year forecast.

  • JNJ Beats, Ups Sales Growth View: Healthcare ETFs in Focus
    Zackslast month

    JNJ Beats, Ups Sales Growth View: Healthcare ETFs in Focus

    Johnson & Johnson continued its long streak of earnings beat and also outpaced revenue estimates. Though it raised the guidance for full-year sales growth, it tightened the earnings per share forecast.

  • Health Day Checkup of Medical ETFs: 5 Top Picks
    Zacks2 months ago

    Health Day Checkup of Medical ETFs: 5 Top Picks

    M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

  • ETF Trends3 months ago

    A Healthy Outlook For Healthcare ETFs

    For example, the iShares US Healthcare ETF (IYH) , which tracks the Dow Jones U.S. Health Care Index, is higher by about 7% this year. The $2.34 billion IYH devotes about 53% of its combined weight to pharmaceuticals and medical equipment stocks. Consequently, investors may also turn to defensive sectors that are less economically sensitive, such as health care.

  • Healthcare ETFs in Focus Ahead of Q4 Earnings
    Zacks4 months ago

    Healthcare ETFs in Focus Ahead of Q4 Earnings

    With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs.

  • JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus
    Zacks4 months ago

    JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus

    Johnson & Johnson expects its sales growth to slow down this year due to pricing pressures and generic-drug competition for its pharmaceutical division. This has put healthcare ETFs in focus.

  • UnitedHealth Pops on Solid Q4: Healthcare ETFs to Buy
    Zacks4 months ago

    UnitedHealth Pops on Solid Q4: Healthcare ETFs to Buy

    ETFs having the largest allocation to UnitedHealth has been in focus post its solid result.

  • ETF Trends5 months ago

    Some Value Remains With HealthCare ETFs

    Compared to other sectors, healthcare was sturdy in 2018 and while the sector looks close to being fairly valued, the group could offer more upside this year. The Health Care Select Sector SPDR ETF (XLV) , the largest healthcare ETF by assets, gained 6.30% last year. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.

  • Best ETFs: After Buying A Top ETF, Don't Forget These 2 Sell Rules
    Investor's Business Daily5 months ago

    Best ETFs: After Buying A Top ETF, Don't Forget These 2 Sell Rules

    Even the best ETFs can cause serious pain for investors when buys are made in the middle of a bear market. Read The Big Picture column for market guidance.

  • 10 Top-Ranked ETFs That Crushed the Market in 2018
    Zacks5 months ago

    10 Top-Ranked ETFs That Crushed the Market in 2018

    While there have been losers in most corner of the space, several ETFs still managed to end the year in green and are likely to continue outperforming in 2019 too.

  • Best ETFs: With Health Care Leading, IShares ETF Comes Out A Winner
    Investor's Business Daily5 months ago

    Best ETFs: With Health Care Leading, IShares ETF Comes Out A Winner

    In a lackluster year for stocks, health care proved to be one of the best sectors, a big reason why iShares U.S. Healthcare is now among the best ETFs.

  • ETF Trends6 months ago

    10 Sector ETFs That Could Stand Out in the New Year

    The U.S. equity rally is beginning to lose steam and investors should not expect markets to maintain their breakneck spurt of yesteryear. Nevertheless, traders may still find value in some battered sectors ...

  • ETF Trends6 months ago

    Stable, Defensive Sector ETFs for a Wobbly Market

    As U.S. markets continue to wobble, investors who want to stay in the game can look to defensive sector-related ETFs for a more steady approach. “If the sell-off continues and it deepens, it’s going to ...

  • ETF Trends6 months ago

    Leveraged Healthcare ETF Gains On Midterm Election Results

    Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...

  • ETF Trends7 months ago

    Healthcare ETFs in Focus Ahead of Election Day

    Count the iShares US Medical Devices ETF (NYSEArca: IHI) and the iShares US Healthcare ETF (NYSEArca: IYH) among the healthcare exchange traded funds that could be affected by the results of the upcoming ...

  • Pfizer’s Market Cap and Shareholding Pattern
    Market Realist7 months ago

    Pfizer’s Market Cap and Shareholding Pattern

    As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.

  • ETF Trends7 months ago

    Health Care ETFs Retreat on DOJ Approval of Aetna-CVS Merger

    The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.

  • Best ETFs & Stocks From the Top Sector of Q3
    Zacks8 months ago

    Best ETFs & Stocks From the Top Sector of Q3

    Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.

  • AbbVie’s Dividend Has Risen 140% since 2013
    Market Realist8 months ago

    AbbVie’s Dividend Has Risen 140% since 2013

    AbbVie (ABBV) announced its fourth-quarter dividend yield of 4.09%. On September 7, AbbVie announced a dividend of $0.96 per share to its shareholders of record on October 15.

  • Thermo Fisher to Offer Complete Cannabis Testing Solutions
    Market Realist8 months ago

    Thermo Fisher to Offer Complete Cannabis Testing Solutions

    Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

  • How Abiomed’s Revenue Trended in the First Quarter
    Market Realist9 months ago

    How Abiomed’s Revenue Trended in the First Quarter

    As discussed earlier, Abiomed (ABMD) reported revenues of $180.0 million in Q1 2019, a 36% increase as compared to revenues of ~$132.5 million in the first quarter of 2018.

  • Investopedia9 months ago

    3 ETFs for Johnson & Johnson's Healthy Breakout

    Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, has underperformed the broader market in 2018. The company's stock is down 3.66% year to date (YTD), while the Standard and Poor's 500 index (S&P 500) is up roughly 7%. David Katz, chief investment officer at Matrix Asset Advisors, told Reuters, "We are much more upbeat about Johnson & Johnson today than we were six months ago.